Related Experiment Video
Updated: Nov 25, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis
Martin J Volz1, Sven T Pleger1, Andreas Weber1
1Division of Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany.
Background:
Percutaneous mitral valve repair (PMVR) is a therapeutic option for severe mitral regurgitation (MR) in patients with heart failure due to differential aetiologies. However, only little is known about the safety and efficacy of this procedure in patients with amyloid cardiomyopathy.
Methods:
Five patients with cardiac amyloidosis and moderate to severe or severe MR undergoing PMVR were analysed retrospectively and compared to seven patients with cardiac amyloidosis and severe MR without intervention. Clinical and functional data, renal function and cardiac biomarkers as well as established risk scores for cardiac amyloidosis were assessed. Primary endpoint was the reduction in MR one year after PMVR. Secondary endpoints were safety, overall mortality after 12 months compared with the control group, as well as changes in clinical and functional parameters.
Results:
Amyloidosis risk assessment documented amyloid cardiomyopathy at an advanced stage in all patients. Procedural, technical and device success of PMVR were all 100% and residual MR remained mild to moderate at 12 months follow-up (P = .038 vs before PMVR). Differences in survival compared with the control (no PMVR) group pointed to a possible survival benefit in the PMVR group (P = .02).
Conclusion:
PMVR is a feasible and safe procedure in patients with cardiac amyloidosis and might carry a possible survival benefit in this patient group.
Insights
Percutaneous mitral valve repair (PMVR) is safe and effective for severe mitral regurgitation in cardiac amyloidosis patients. This procedure may offer a survival benefit compared to no intervention.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Amyloidosis Research
Background:
- Severe mitral regurgitation (MR) impacts heart failure patients.
- Limited data exists on percutaneous mitral valve repair (PMVR) safety and efficacy in cardiac amyloidosis.
Purpose of the Study:
- To evaluate the safety and efficacy of PMVR in patients with cardiac amyloidosis and severe MR.
- To compare outcomes of PMVR versus no intervention in this patient population.
Main Methods:
- Retrospective analysis of five patients with cardiac amyloidosis undergoing PMVR.
- Comparison with seven control patients with cardiac amyloidosis not receiving PMVR.
- Assessment of clinical, functional, renal, and biomarker data; evaluation of MR reduction and survival at 12 months.
Main Results:
- PMVR demonstrated 100% procedural, technical, and device success.
- Significant reduction in MR was observed at 12 months (P=.038).
- The PMVR group showed a potential survival benefit compared to the control group (P=.02).
Conclusions:
- PMVR is a feasible and safe intervention for cardiac amyloidosis patients with severe MR.
- The procedure may be associated with improved survival in this high-risk group.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Stenosis I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse I: Introduction
Mitral Regurgitation III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests

